Pls_老虎社区_美港股上老虎

Karen2A
2021-12-08

Pls

Even Good Penny Stocks Like Senseonics Aren’t Always Profitable

SENS stock's tech can outpace competitors, but it still risks losing the glucose monitoring race

Even Good Penny Stocks Like Senseonics Aren’t Always Profitable

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":606557635,"tweetId":"606557635","gmtCreate":1638904185607,"gmtModify":1638904185607,"author":{"id":4101718080434010,"idStr":"4101718080434010","authorId":4101718080434010,"authorIdStr":"4101718080434010","name":"Karen2A","avatar":"https://static.tigerbbs.com/361e0cbe05bb05eee97be770b2ec0f25","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Pls&nbsp;</body></html>","htmlText":"<html><head></head><body>Pls&nbsp;</body></html>","text":"Pls","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/606557635","repostId":1115674384,"repostType":2,"repost":{"id":"1115674384","kind":"news","pubTimestamp":1638775462,"share":"https://www.laohu8.com/m/news/1115674384?lang=&edition=full","pubTime":"2021-12-06 15:24","market":"us","language":"en","title":"Even Good Penny Stocks Like Senseonics Aren’t Always Profitable","url":"https://stock-news.laohu8.com/highlight/detail?id=1115674384","media":"InvestorPlace","summary":"SENS stock's tech can outpace competitors, but it still risks losing the glucose monitoring race","content":"To call&nbsp;Senseonics Holdings(NYSEAMERICAN:SENS) a penny stock isn’t to say it sells for a penny. The phrase refers to any stock with a low price and low market capitalization, and SENS stock currently goes for about $2.70 per share. Such stocks are always speculative, and the low market cap makes them easy for investors to manipulate.\nSenseonics&nbsp;makes Eversense, an implanted glucose monitor for diabetics. The latest version can take measurements&nbsp;for six months. The version on the market today runs for just&nbsp;three months, but that’s still longer than its competitors.\nSenseonics went public over five years ago in March 2016. It priced its&nbsp;15.8 million shares&nbsp;at $2.85 each. As of the morning of Dec. 2, the stock was at the same price. This doesn’t mean SENS stock has gone nowhere. There are now almost 446 million shares outstanding.\nThe SENS Stock Story\nThe Senseonics story is one of great promise, but not great results. The Dec. 2 market cap of $1.27 billion supports sales of $13.6 million over the last four quarters.\nIf you have severe diabetes, however,Eversense is cool. The sensor, implanted in an arm, is not much bigger than a thick grain of rice. The transmitter sits outside the arm. It is removable, rechargeable and water resistant.\nIt’s also&nbsp;pretty accurate. The data runs through a service provider called&nbsp;Ascensia, which was&nbsp;created from&nbsp;former units of&nbsp;Panasonic(OTCMKTS:PCRFY) and&nbsp;Bayer(OTCMKTS:BAYRY). You can see the results on a mobile app or a smart watch.\nThe product has gone through multiple rounds of hype and disappointment. When the hype was high, Senseonics sold stock. When disappointment came in, the price fell.\nIn September, Senseonics had&nbsp;a premarket approval supplement application&nbsp;before the Food and Drug Administration. The hope was that if the application was approved,sales could jump&nbsp;to $150 million to 200 million in a few years. As things currently stand, you’re paying&nbsp;$6,400 per year&nbsp;for the product and service.\nHopes also ran high when SENS stock was&nbsp;picked up by traderson&nbsp;Reddit. At one point in February, the shares traded at $5.56. Our Chris Markoch recently wrote about Senseonics having the potential for&nbsp;10x gains in 2022.\nThe Penny Stock Story\nI have a basic prejudice against penny stocks. That is, if these ideas are so great, why haven’t venture capitalists jumped on it? Why does management need your money to reach the market?\nIn the case of Senseonics, the argument is one of time. It may take a decade for the company’s approach to prove itself. Meanwhile, it faces competition from&nbsp;Dexcom(NASDAQ:DXCM). This rival company has endorsements from singers&nbsp;Nick Jonas and Patti LaBelle&nbsp;and costs $300 per month for a sensor that lasts 10 days. There’s also&nbsp;Abbott Laboratories&nbsp;(NYSE:ABT), which offers a system called&nbsp;MyFreeStyle&nbsp;with a sensor that lasts 14 days.\nThen there’s&nbsp;Apple(NASDAQ:AAPL), which is rumored to have plans for a glucose monitoring system&nbsp;inside Version 8&nbsp;of the Apple Watch, using short-wavelength infrared sensors.\nSenseonics has a long-running, accurate sensor, and if insurers pick it up so the price to patients drop, sales could jump. But it’s not alone in the market.\nThe Bottom Line on SENS Stock\nSenseonics is what I call a “good” penny stock. It’s working on a real product with serious potential. The company has been developing and refining its offering for many years, and the latest version shows promise.\nBut a small company&nbsp;can only run so fast.A surgical implant that lasts six months won’t win against a service using radio waves inside an Apple Watch.\nEven if Senseonics achieves $150 million in sales, you’re still paying 10 times revenue for SENS stock. You don’t know its profitability compared to Abbott and Dexcom. Plus, Apple could blow it out of the water on costs.\nThe great future Senseonics promises might not arrive.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Even Good Penny Stocks Like Senseonics Aren’t Always Profitable</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEven Good Penny Stocks Like Senseonics Aren’t Always Profitable\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 15:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/even-good-penny-stocks-like-senseonics-arent-always-profitable/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nTo call Senseonics Holdings(NYSEAMERICAN:SENS) a penny stock isn’t to say it sells for a penny. The phrase refers to any stock with a low price and low market capitalization, and SENS stock currently ...\n\n<a href=\"https://investorplace.com/2021/12/even-good-penny-stocks-like-senseonics-arent-always-profitable/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SENS":"Senseonics Holdings,Inc."},"source_url":"https://investorplace.com/2021/12/even-good-penny-stocks-like-senseonics-arent-always-profitable/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115674384","content_text":"To call Senseonics Holdings(NYSEAMERICAN:SENS) a penny stock isn’t to say it sells for a penny. The phrase refers to any stock with a low price and low market capitalization, and SENS stock currently goes for about $2.70 per share. Such stocks are always speculative, and the low market cap makes them easy for investors to manipulate.\nSenseonics makes Eversense, an implanted glucose monitor for diabetics. The latest version can take measurements for six months. The version on the market today runs for just three months, but that’s still longer than its competitors.\nSenseonics went public over five years ago in March 2016. It priced its 15.8 million shares at $2.85 each. As of the morning of Dec. 2, the stock was at the same price. This doesn’t mean SENS stock has gone nowhere. There are now almost 446 million shares outstanding.\nThe SENS Stock Story\nThe Senseonics story is one of great promise, but not great results. The Dec. 2 market cap of $1.27 billion supports sales of $13.6 million over the last four quarters.\nIf you have severe diabetes, however,Eversense is cool. The sensor, implanted in an arm, is not much bigger than a thick grain of rice. The transmitter sits outside the arm. It is removable, rechargeable and water resistant.\nIt’s also pretty accurate. The data runs through a service provider called Ascensia, which was created from former units of Panasonic(OTCMKTS:PCRFY) and Bayer(OTCMKTS:BAYRY). You can see the results on a mobile app or a smart watch.\nThe product has gone through multiple rounds of hype and disappointment. When the hype was high, Senseonics sold stock. When disappointment came in, the price fell.\nIn September, Senseonics had a premarket approval supplement application before the Food and Drug Administration. The hope was that if the application was approved,sales could jump to $150 million to 200 million in a few years. As things currently stand, you’re paying $6,400 per year for the product and service.\nHopes also ran high when SENS stock was picked up by traderson Reddit. At one point in February, the shares traded at $5.56. Our Chris Markoch recently wrote about Senseonics having the potential for 10x gains in 2022.\nThe Penny Stock Story\nI have a basic prejudice against penny stocks. That is, if these ideas are so great, why haven’t venture capitalists jumped on it? Why does management need your money to reach the market?\nIn the case of Senseonics, the argument is one of time. It may take a decade for the company’s approach to prove itself. Meanwhile, it faces competition from Dexcom(NASDAQ:DXCM). This rival company has endorsements from singers Nick Jonas and Patti LaBelle and costs $300 per month for a sensor that lasts 10 days. There’s also Abbott Laboratories (NYSE:ABT), which offers a system called MyFreeStyle with a sensor that lasts 14 days.\nThen there’s Apple(NASDAQ:AAPL), which is rumored to have plans for a glucose monitoring system inside Version 8 of the Apple Watch, using short-wavelength infrared sensors.\nSenseonics has a long-running, accurate sensor, and if insurers pick it up so the price to patients drop, sales could jump. But it’s not alone in the market.\nThe Bottom Line on SENS Stock\nSenseonics is what I call a “good” penny stock. It’s working on a real product with serious potential. The company has been developing and refining its offering for many years, and the latest version shows promise.\nBut a small company can only run so fast.A surgical implant that lasts six months won’t win against a service using radio waves inside an Apple Watch.\nEven if Senseonics achieves $150 million in sales, you’re still paying 10 times revenue for SENS stock. You don’t know its profitability compared to Abbott and Dexcom. Plus, Apple could blow it out of the water on costs.\nThe great future Senseonics promises might not arrive.","news_type":1,"symbols_score_info":{"SENS":0.9}},"isVote":1,"tweetType":1,"viewCount":2081,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}